Shares of MannKind Co. (NASDAQ:MNKD) have earned a consensus rating of “Hold” from the eight analysts that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $1.89.
Several equities research analysts have recently weighed in on the stock. BidaskClub raised shares of MannKind from a “sell” rating to a “hold” rating in a research report on Saturday. S&P Equity Research lowered their price objective on shares of MannKind from $3.49 to $2.77 in a research report on Thursday, January 25th. ValuEngine downgraded shares of MannKind from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Zacks Investment Research raised shares of MannKind from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, Maxim Group reaffirmed a “hold” rating on shares of MannKind in a research report on Tuesday, January 30th.
Shares of MannKind (NASDAQ:MNKD) opened at $2.61 on Monday. The firm has a market cap of $299.82, a PE ratio of -9.67 and a beta of 3.18. MannKind has a 1 year low of $0.67 and a 1 year high of $6.96. The company has a debt-to-equity ratio of -0.43, a current ratio of 0.31 and a quick ratio of 0.28.
Several large investors have recently made changes to their positions in the stock. BlackRock Inc. grew its position in shares of MannKind by 82.8% during the 4th quarter. BlackRock Inc. now owns 3,534,811 shares of the biopharmaceutical company’s stock valued at $8,201,000 after buying an additional 1,600,802 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of MannKind by 63.3% during the 4th quarter. Wells Fargo & Company MN now owns 146,916 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 56,965 shares during the last quarter. Dupont Capital Management Corp boosted its stake in MannKind by 99.9% during the 4th quarter. Dupont Capital Management Corp now owns 201,900 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 100,900 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in MannKind by 60.5% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 188,428 shares of the biopharmaceutical company’s stock valued at $438,000 after purchasing an additional 71,012 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in MannKind during the 3rd quarter valued at about $270,000. 12.25% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/12/mannkind-co-mnkd-given-consensus-recommendation-of-hold-by-analysts.html.
MannKind Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.